Back to Search
Start Over
Metastatic Mucinous Ovarian Cancer and Treatment Decisions Based on Histology and Molecular Markers Rather Than the Primary Location
- Source :
- Journal of the National Comprehensive Cancer Network. 10:1076-1080
- Publication Year :
- 2012
- Publisher :
- Harborside Press, LLC, 2012.
-
Abstract
- Approximately 22,000 cases of ovarian cancer occur each year in the United States, and likely fewer than 2000 cases of mucinous ovarian cancers. Although 90% of patients with mucinous ovarian cancer present with stage I disease and have curative surgeries, advanced-stage disease is known to have a poor response to standard platinum- and taxane-based chemotherapy. Despite limited enthusiasm, standard chemotherapy is still recommended for most patients with advanced-stage mucinous malignancies of the ovary. This report presents an unusual case of a woman with HER2-positive metastatic mucinous carcinoma of the ovary treated with chemotherapy regimens typically used for colorectal malignancies, followed by epidermal growth factor receptor-targeted therapies.
- Subjects :
- Oncology
medicine.medical_specialty
Lung Neoplasms
Bevacizumab
Receptor, ErbB-2
medicine.medical_treatment
Ovary
Antibodies, Monoclonal, Humanized
Cystadenocarcinoma, Mucinous
Lapatinib
Young Adult
Trastuzumab
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
Biomarkers, Tumor
medicine
Humans
Mucinous carcinoma
Cystadenocarcinoma
Ovarian Neoplasms
Chemotherapy
Brain Neoplasms
Vascular Endothelial Growth Factors
business.industry
medicine.disease
ErbB Receptors
medicine.anatomical_structure
Quinazolines
Female
Ovarian cancer
business
medicine.drug
Subjects
Details
- ISSN :
- 15401413 and 15401405
- Volume :
- 10
- Database :
- OpenAIRE
- Journal :
- Journal of the National Comprehensive Cancer Network
- Accession number :
- edsair.doi.dedup.....e714ea21644a6b579651000719f7a0e1